Nuvation Bio (NUVB) Stock Forecast, Price Target & Predictions
NUVB Stock Forecast
Nuvation Bio stock forecast is as follows: an average price target of $7.00 (represents a 129.51% upside from NUVB’s last price of $3.05) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
NUVB Price Target
The average price target for Nuvation Bio (NUVB) is $7.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $5.00. This represents a potential 129.51% upside from NUVB's last price of $3.05.
NUVB Analyst Ratings
According to 4 Wall Street analysts, Nuvation Bio's rating consensus is 'Buy'. The analyst rating breakdown for NUVB stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Nuvation Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 17, 2024 | Kennen MacKay | RBC Capital | $5.00 | $2.81 | 77.94% | 63.93% |
| Mar 28, 2024 | Robert Burns | H.C. Wainwright | $8.00 | $3.97 | 101.51% | 162.30% |
| Mar 27, 2024 | Michael Yee | Jefferies | $10.00 | $2.88 | 247.22% | 227.87% |
| Mar 26, 2024 | Kaveri Pohlman | BTIG | $5.00 | $2.25 | 122.22% | 63.93% |
| Jan 06, 2023 | - | Jefferies | $2.00 | $2.03 | -1.48% | -34.43% |
| May 04, 2022 | - | H.C. Wainwright | $14.00 | $4.78 | 192.89% | 359.02% |
The latest Nuvation Bio stock forecast, released on Apr 17, 2024 by Kennen MacKay from RBC Capital, set a price target of $5.00, which represents a 77.94% increase from the stock price at the time of the forecast ($2.81), and a 63.93% increase from NUVB last price ($3.05).
Nuvation Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $7.00 |
| Last Closing Price | $3.05 | $3.05 | $3.05 |
| Upside/Downside | -100.00% | -100.00% | 129.51% |
In the current month, the average price target of Nuvation Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Nuvation Bio's last price of $3.05. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 17, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Mar 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 27, 2024 | Jefferies | Hold | Buy | Upgrade |
| Mar 26, 2024 | BTIG | - | Buy | Upgrade |
| Jan 07, 2023 | Jefferies | - | Hold | Downgrade |
Nuvation Bio's last stock rating was published by RBC Capital on Apr 17, 2024. The company gave NUVB a "Outperform" rating, the same as its previous rate.
Nuvation Bio Financial Forecast
Nuvation Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M |
| High Forecast | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M |
| Low Forecast | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Nuvation Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NUVB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Nuvation Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict NUVB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Nuvation Bio's previous annual EBITDA (undefined) of $NaN.
Nuvation Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-37.18M | $-35.02M | $-32.57M | $-30.32M | $-30.97M | $-30.51M | $-14.31M |
| High Forecast | $-37.18M | $-35.02M | $-32.57M | $-30.32M | $-30.97M | $-17.80M | $-14.31M |
| Low Forecast | $-37.18M | $-35.02M | $-32.57M | $-30.32M | $-30.97M | $-45.77M | $-14.31M |
| Surprise % | - | - | - | - | - | - | - |
Nuvation Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NUVB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Nuvation Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Nuvation Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NUVB last annual SG&A of $NaN (undefined).
Nuvation Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.15 | $-0.14 | $-0.13 | $-0.12 | $-0.13 | $-0.12 | $-0.06 |
| High Forecast | $-0.15 | $-0.14 | $-0.13 | $-0.12 | $-0.13 | $-0.07 | $-0.06 |
| Low Forecast | $-0.15 | $-0.14 | $-0.13 | $-0.12 | $-0.13 | $-0.19 | $-0.06 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Nuvation Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NUVB previous annual EPS of $NaN (undefined).
Nuvation Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.37 | $10.00 | 629.93% | Buy |
| CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
| ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
| NUVB | Nuvation Bio | $3.05 | $7.00 | 129.51% | Buy |
| NXTC | NextCure | $1.40 | $3.00 | 114.29% | Buy |
| TIL | Instil Bio | $84.52 | $17.67 | -79.09% | Hold |
NUVB Forecast FAQ
Is Nuvation Bio a good buy?
Yes, according to 4 Wall Street analysts, Nuvation Bio (NUVB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of NUVB's total ratings.
What is NUVB's price target?
Nuvation Bio (NUVB) average price target is $7 with a range of $5 to $10, implying a 129.51% from its last price of $3.05. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Nuvation Bio stock go up soon?
According to Wall Street analysts' prediction for NUVB stock, the company can go up by 129.51% (from the last price of $3.05 to the average price target of $7), up by 227.87% based on the highest stock price target, and up by 63.93% based on the lowest stock price target.
Can Nuvation Bio stock reach $5?
NUVB's average twelve months analyst stock price target of $7 supports the claim that Nuvation Bio can reach $5 in the near future.
What are Nuvation Bio's analysts' financial forecasts?
Nuvation Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $4.3M (high $4.3M, low $4.3M), average EBITDA is $0 (high $0, low $0), average net income is $-75.792M (high $-63.078M, low $-91.049M), average SG&A $0 (high $0, low $0), and average EPS is $-0.31 (high $-0.258, low $-0.372). NUVB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5.74M (high $5.74M, low $5.74M), average EBITDA is $0 (high $0, low $0), average net income is $-135M (high $-135M, low $-135M), average SG&A $0 (high $0, low $0), and average EPS is $-0.552 (high $-0.552, low $-0.552).